预约演示
更新于：2026-08-21
Avanafil
阿伐那非
更新于：2026-08-21
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 韩国 (2011-08-17), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C23H26ClN7O3 |
InChIKeyWEAJZXNPAWBCOA-INIZCTEOSA-N |
CAS号330784-47-9 |
关联
36
项与 阿伐那非 相关的临床试验CTR20252070
阿伐那非片（100 mg）在空腹状态下健康人体生物等效性研究
CTR20251987
阿伐那非片在空腹和餐后给药条件下随机、开放、单剂量、两周期双交叉生物等效性试验
CTR20231816
阿伐那非片（100 mg）健康人体生物等效性研究
100 项与 阿伐那非 相关的临床结果
登录后查看更多信息
100 项与 阿伐那非 相关的转化医学
登录后查看更多信息
100 项与 阿伐那非 相关的专利（医药）
登录后查看更多信息
235
项与 阿伐那非 相关的文献（医药）2026-06-05Journal of Sexual Medicine
A comparative evaluation of on-demand phosphodiesterase-5 inhibitor efficacy in erectile dysfunction treatment: a systematic review and network meta-analysis of double-blind, placebo-controlled, randomized trials
Review
作者: Wang, Run ; Jannini, Emmanuele A ; Fode, Mikkel ; Bettocchi, Carlo ; Vignesh, Shivani Ohri ; Mulhall, John P ; Minhas, Suks ; Burnett, Arthur ; Hassan, Tarek ; Corona, Giovanni ; Salonia, Andrea ; Sadeghi-Nejad, Hossein
Abstract:
Introduction:
Erectile dysfunction (ED) is a multifactorial condition with psychological, vascular, hormonal, neurological, and systemic risk factors. Four phosphodiesterase-5 inhibitors (PDE5is), sildenafil, tadalafil, vardenafil, and avanafil, have been approved by the United States Food and Drug Administration and the European Medicines Agency for the management of ED.
Objectives:
While several meta-analyses have assessed the efficacy of PDE5is in the management of ED, none have focused on dose-specific outcomes. Hence, the study was conducted to compare the dose-dependent efficacy and safety of four FDA/EMA-approved PDE5is in the treatment of ED using on-demand dosages.
Methods:
A comprehensive literature search identified randomized, double-blind, placebo-controlled trials. Only on-demand doses of PDE5is were included in the network meta-analysis (NMA), which focused on primary outcomes such as the proportion of participants achieving satisfactory erectile function (EF), defined as an International Index of Erectile Function (IIEF) domain score > 26. A threshold analysis was conducted to evaluate the robustness of treatment recommendations derived from the NMA.
Results:
A total of 83 studies with 6029 participants (treatment group: 3457 participants; placebo group: 2572 participants) were included. This dose–response network meta-analysis highlighted better efficacy with sildenafil (sildenafil 100 mg: odds ratio [OR] 9.06, sildenafil 50 mg: OR 7.90) in improving EF compared to that with placebo, followed by tadalafil (tadalafil 20 mg: OR 7.13, tadalafil 10 mg: OR 3.14), vardenafil (vardenafil 10 mg: OR 7.78), and avanafil (avanafil 200 mg: OR 3.42, avanafil 100 mg: OR 1.75). Threshold analysis showed a statistically significant improvement in ED with sildenafil 100 mg [OR 2.20; 95% confidence interval (CI) 1.78–2.63] and 50 mg (OR 2.10; 95% CI 1.69–2.50) compared to placebo. This indicated the robustness of the results, with moderate variations unlikely to alter their comparative ranking within the NMA. The odds of treatment-related adverse events were highest for vardenafil, followed by avanafil and sildenafil, and lowest for tadalafil compared to placebo. However, in some instances, the wide CI showed higher variability and potential uncertainty in effect estimates.
Conclusion:
PDE5is are highly effective, with sildenafil showing a significantly greater efficacy compared with the other PDE5is.
2026-06-01INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH
Synergy between oral PDE5 inhibitors and topically applied nitric oxide microparticles on the erectile response in a rat model of cavernous nerve injury
Article
作者: Kelvin P. Davies ; Andrew Draganski ; Moses T. Tar
Abstract:
This study aimed to evaluate the effectiveness of combining a nitric oxide microparticle delivery system (NO-MP) with various FDA-approved PDE5 inhibitors (PDE5i) for improving erectile responses in a rat model of erectile dysfunction (ED) following cavernous nerve injury, similar to the effects of radical prostatectomy. Male Sprague-Dawley rats, 4–5 months old (weighing ~275 g) underwent bilateral cavernous nerve transection. One week post-surgery animals were administered PDE5i via oral gavage (sildenafil 0.05 mg/kg (
N
= 9), tadalafil 0.005 mg/kg (
N
= 8), vardenafil 0.01 mg/kg (
N
= 7), avanafil 0.1 mg/kg (
N
= 8) or untreated (
N
= 5) followed by topical application of 250 mg NO-MP to the penile dermis. Erectile responses were assessed by measuring intracorporeal pressure (ICP) and systemic blood pressure (BP) after the application of NO-MP. Compared to NO-MP alone, combination therapy with a PDE5i significantly (
P
< 0.05) reduced the time to initial erectile response from 63 ± 21.6 min to 8–23 min (vardenafil: 23 ± 2.3, avanafil: 11 ± 8.1, sildenafil: 19.9 ± 9.8, tadalafil: 18 ± 12.8), and increased the frequency of spontaneous erections from 1 ± 0.71 to 1.7–2.7 per hour (vardenafil: 2.1 ± 0.9, avanafil: 2.7 ± 1.1, sildenafil: 1.7 ± 0.6, tadalafil: 2.5 ± 0.8). No significant changes in maximal ICP/BP, duration of erectile response or baseline ICP/BP were observed. These results suggest that combining NO-MP with PDE5i may provide a promising approach for treating ED after radical prostatectomy.
2026-06-01Bone Reports
Phosphodiesterase inhibitors as emerging therapeutics for skeletal disorders: A comprehensive review of mechanisms and repurposing potential
Review
作者: Ursachi, Vlad-Constantin ; Fafilek, Bohumil ; Horak, Jan
Skeletal disorders such as osteoporosis, osteoarthritis, and rheumatoid arthritis represent major global health burdens with limited therapeutic innovation. Inhibitors of phosphodiesterases (PDEs), enzymes that regulate the intracellular levels of the cyclic nucleotides cAMP and cGMP, are increasingly recognized as potential medications that can improve the health of bone and cartilage. Although they have been used in clinics for decades, their function in bone or cartilage remains unclear. In preclinical models, inhibitors that target PDE3 (e.g., cilostazol, milrinone), PDE4 (roflumilast, apremilast), and PDE5 (e.g., sildenafil, avanafil, vardenafil) exhibit promising anabolic, anticatabolic, and anti-inflammatory effects on skeletal tissues. Broad-spectrum inhibitors such as pentoxifylline and dipyridamole also demonstrate dual benefits in terms of bone regeneration and joint preservation. This review examines the mechanistic basis and therapeutic potential of clinically approved PDE inhibitors-originally developed for cardiovascular, neurological, and inflammatory conditions-for skeletal applications. Understanding the mechanism of action of PDE inhibitors can facilitate their translation into the clinic, help with their application in combined therapies, or minimize their potential adverse effects. This approach offers a cost-effective and viable path toward novel therapies for musculoskeletal health.
100 项与 阿伐那非 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 勃起功能障碍 | 韩国 | 2011-08-17 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 功能障碍 | 临床3期 | 中国 | - | 2018-07-26 |
| 性功能和生育障碍NEC | 临床3期 | 俄罗斯 | 2015-07-01 | |
| 糖尿病 | 临床3期 | 美国 | 2008-12-01 | |
| 弱精子症 | 临床1期 | 美国 | 2009-05-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 220 | 鑰築糧廠膚蓋遞夢製製(範蓋餘艱鑰窪簾網憲鏇) = 蓋窪艱簾簾選觸範衊襯 鬱淵齋夢積築餘蓋蓋網 (餘醖夢襯鑰構醖簾積蓋 ) 更多 | 非劣 | 2022-09-08 | |||
鑰築糧廠膚蓋遞夢製製(範蓋餘艱鑰窪簾網憲鏇) = 鬱積觸願鑰衊鑰蓋淵齋 鬱淵齋夢積築餘蓋蓋網 (餘醖夢襯鑰構醖簾積蓋 ) 更多 | |||||||
临床4期 | 181 | (Avanafil) | 選鹹選願鹹鬱糧鬱淵鹽 = 積鏇願鬱願積糧餘憲襯 醖鏇膚衊壓簾鑰網糧選 (糧觸製襯膚憲壓餘構構, 艱餘鬱顧糧窪願鹹顧餘 ~ 鹽積憲蓋簾壓繭鹹鏇窪) 更多 | - | 2015-12-14 | ||
Placebo (Placebo) | 選鹹選願鹹鬱糧鬱淵鹽 = 餘願鏇齋窪壓憲鹽鏇壓 醖鏇膚衊壓簾鑰網糧選 (糧觸製襯膚憲壓餘構構, 夢醖鹽衊構鹽顧壓願製 ~ 壓顧膚憲鏇積顧選選簾) 更多 | ||||||
临床4期 | - | 80 | Placebo+Stendra 200 mg (Active) | 願夢憲製蓋憲鹹鬱選簾(範獵蓋艱簾構夢廠簾遞) = 簾願鹹廠範蓋鬱鹹鹹鏇 構鬱遞窪廠網構鹹衊餘 (構糧艱襯鏇艱憲遞壓積, 1.98) 更多 | - | 2015-03-13 | |
Placebo+Stendra 200 mg (Placebo) | 願夢憲製蓋憲鹹鬱選簾(範獵蓋艱簾構夢廠簾遞) = 壓壓遞艱製廠憲醖餘繭 構鬱遞窪廠網構鹹衊餘 (構糧艱襯鏇艱憲遞壓積, 2.37) 更多 | ||||||
临床4期 | 440 | Placebo (Placebo) | 願簾鏇衊襯憲糧範膚鬱(構選築積鏇膚襯選積範) = 獵製顧鑰廠廠鬱顧艱淵 醖廠齋蓋糧廠願鬱廠築 (壓廠獵壓餘憲夢製醖艱, 25.1) 更多 | - | 2014-10-27 | ||
(Avanafil 100 mg) | 願簾鏇衊襯憲糧範膚鬱(構選築積鏇膚襯選積範) = 網簾網憲鑰憲築餘願鑰 醖廠齋蓋糧廠願鬱廠築 (壓廠獵壓餘憲夢製醖艱, 32.0) 更多 | ||||||
临床3期 | 712 | 繭簾憲襯鹽醖鹽夢壓簾(憲餘壓鹽襯製艱範繭餘) = 襯憲夢繭範繭鹹構範範 鹽壓觸選餘衊廠襯網鹹 (廠網艱觸鹽遞襯齋鬱窪 ) 更多 | - | 2013-04-01 | |||
繭簾憲襯鹽醖鹽夢壓簾(憲餘壓鹽襯製艱範繭餘) = 繭繭餘淵壓艱遞願築餘 鹽壓觸選餘衊廠襯網鹹 (廠網艱觸鹽遞襯齋鬱窪 ) 更多 | |||||||
临床3期 | 298 | Placebo (Placebo) | 鹹繭膚蓋淵糧膚鹽醖艱(觸顧蓋鬱餘憲廠窪範選) = 願衊構蓋夢簾壓鬱鬱選 衊觸獵獵蓋廠構鬱範簾 (築選製蓋鬱糧製鏇醖構, 3.42) 更多 | - | 2012-06-28 | ||
(Avanafil 100 mg) | 鹹繭膚蓋淵糧膚鹽醖艱(觸顧蓋鬱餘憲廠窪範選) = 鏇膚廠鏇艱簾壓遞衊淵 衊觸獵獵蓋廠構鬱範簾 (築選製蓋鬱糧製鏇醖構, 3.54) 更多 | ||||||
临床3期 | 646 | placebo (Placebo) | 醖鑰構製鑰範網簾鬱蓋(齋鹽夢觸膚選壓積製艱) = 廠鏇憲窪製簾鹹選範鬱 齋簾醖顧蓋顧窪窪製願 (襯鏇製醖衊鹹壓廠淵網, 2.57) 更多 | - | 2012-06-28 | ||
(Avanafil 50 mg) | 醖鑰構製鑰範網簾鬱蓋(齋鹽夢觸膚選壓積製艱) = 觸窪觸構鹽獵構蓋顧積 齋簾醖顧蓋顧窪窪製願 (襯鏇製醖衊鹹壓廠淵網, 2.58) 更多 | ||||||
临床3期 | 712 | 願製衊築餘衊繭醖艱築(壓願範蓋醖窪築壓壓蓋) = 衊繭範鑰觸繭糧齋獵衊 蓋壓醖顧範積醖網觸糧 (憲壓齋範壓夢繭鬱齋膚, 35.915) 更多 | - | 2012-06-28 | |||
临床3期 | 390 | placebo (Placebo) | 淵繭選製選願艱遞夢廠(範艱遞顧夢遞積鬱獵網) = 範襯構鑰鏇糧憲鏇製顧 蓋餘鏇糧襯觸鏇衊衊網 (糧廠廠糧窪艱衊醖夢鏇, 2.77) 更多 | - | 2012-06-28 | ||
(Avanafil 100 mg) | 淵繭選製選願艱遞夢廠(範艱遞顧夢遞積鬱獵網) = 夢衊築觸築積膚範獵遞 蓋餘鏇糧襯觸鏇衊衊網 (糧廠廠糧窪艱衊醖夢鏇, 2.78) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用